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2_5A[ppp(A2’p),5’A] has been implicated as a mediator in the antiviral action of interferon. Its direct evalu- 
ation as an indicator of virus replication is hampered by two limitations: its inability to penetrate intact 
cells, and its rapid intracellular degradation by (2’-5’)phosphodiesterase. These problems could be overcome 
by using a microinjection technique whereby a phosphodiesterase-resistant analog of 2-A, in which the 2’- 
terminals adenosine residue is replaced by 2-(9-adenyl)-6-hydroxy-methyl-4-hexylmorpholine. was injected 
into individual HeLa cells before infection with mengovirus or vesicular stomatitis virus (VSV). This 
comparative assay with two representatives of different virus classes in a single experimental system pomted 
to the high sensitivity of VSV to inhibition by 225A oligonucleotides, in contrast with the low sensitivity 
of mengovirus. Microinjection of the hexylmorpholine 225A analog led to a much greater reduction in 
mengovirus yield than did microinjection of 2-5A itself. 
Antiviral ativity Microinjection 
1. INTRODUCTION 
In the presence of dsRNA, 2-5A synthetase(s) 
convert ATP to a series of unusual 
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Abbreviations: dsRNA, double-stranded RNA; 2-5A, 
2 ’ -5 ’ -oligonucleotides with the general structure 
ppp(A2’p),5’A (n = 2 + trimer, n = 3 -+ tetramer); 
core 2-5A, 5 ’ -dephosphorylated 2-5A, thus 
(A2 ’ p),5 ‘ A; RNase L, 2-SA-activated endoribonucle- 
ase, also called ribonuclease F; EMC virus, encephalo- 
myocarditis virus; xylo 2-5A core, xyloadenosine 
analogue with the general structure (xyloA2’ p)zxyloA; 
hexylmorpholine 2-5A analog, 2-5A in which the 
ribose of the 2’-terminal nucleotide is transformed to an 
N-hexylmorpholine (azahexapyranose), specifically, 
2-(adeny])-6-hydroxymethyl-4-hexylmorpholine 
2-SA analog Interferon 
oligonucleotides with the general structure 
ppp(A2’p),5’A (n = l-14), referred to as 2-5A 
[l-4]. These oligonucleotides pecifically activate 
an endoribonuclease, RNase L, that is responsible 
for the cleavage of mRNA [5] and rRNA [6]. Some 
structural requirements for the activation of this 
nuclease in vitro have been established [7-181. The 
production of 2-5A has been demonstrated in 
several interferon (IFN)-treated virus-infected cell 
systems; in IFN-treated EMC virus-infected L 
cells, both the triphosphate (2-5A) and its core 
were detected by HPLC, radioimmuno and 
radiobinding assays, and the appearance of these 
products correlated with the establishment of the 
antiviral state [7-191. That RNase L is activated 
under these conditions was attested to by the 
degradation of rRNA and EMC virus RNA 
[20,21]. Furthermore, the synthesis of 2-5A seems 
to protect IFN-treated HeLa cells infected with 
reovirus and is accompanied by reovirus mRNA 
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degradation [22]. A similar situation may occur in 
vaccinia virus-infected cells [23] and Semliki Forest 
virus-infected cells [24]. However, in a number of 
virus-cell systems, the contribution of the 2-5A- 
mediated activation of RNase L to the overall an- 
tiviral activity could not be ascertained ([25-271; 
reviews [28,29]). 
Attempts have been directed at stimulating the 
uptake of 2-SA oligonucleotides in intact cells by 
permeabilising the cells, either by hypertonic salt 
treatment or calcium phosphate precipitation, or 
by incubating the cells with high concentrations of 
2-5A core [6-81. However, such procedures did 
not permit quantitative assessment of the struc- 
tural requirements of the 2-5A analogs for RNase 
L activation, i.e. because of the membrane damage 
ensuing from these procedures as well as the low 
stability of 2-5A itself [8,30-321. 
At least two other enzymes are involved in the 
2-5A pathway: (i) a phosphodiesterase, which 
specifically cleaves (2’ -5 ‘)-phosphodiester link- 
ages, starting at the 2’-terminus; the induction of 
this enzyme by IFN has been demonstrated only in 
mouse L cells [33] and its role in intact cells is not 
yet understood [34]; (ii) one or several 
phosphatases able to dephosphorylate 2-5A to its 
core; the occurrence of this (these) enzyme(s) in in- 
tact cells are/is also not clear [28]. The presence of 
these two enzymes may account for the rapid 
degradation of 2-5A in intact cells and cell ex- 
tracts. Therefore, several analogs of 2-SA have 
been synthesized either chemically or enzymatical- 
ly with the aim to increase their metabolic stability 
toward degradative enzymes [11,12,14,15,35]. 
In fact, the 2’-terminal ribose and in particular 
its 3 ‘-OH group are not required for either RNase 
L binding or activation [9], although the free 2 ’ - 
and 3’-OH groups of the 2’-terminal ribose are 
essential for degradation by phosphodiesterase. 
Imai et al. [36] have transformed the 2’-terminal 
ribose of 2-5A to an N-substituted morpholine 
(azahexapyranose) [The analog used in these 
studies was a tetraadenylate in which the 2’-ter- 
minal adenosine residue was converted to 2-(9- 
adenyl)-6-hydroxymethyl-4-hexylmorpholine, also 
referred to as 9-(3’-aza-4’-hexyl-1’,2’,3’,4’-tetra- 
deoxyhexopyranos-1 ‘-yl)adenine. For the sake of 
convenience it will be referred to as ‘tailed’ 2-5A 
analog.], thus obtaining a molecule resistant to 
phosphodiesterase degradation without affecting 
RNase L binding or activation. As a triphosphate, 
this 2-5A analog cannot be taken up by the cells 
unless they are permeabilized, and so far the activi- 
ty of this analog has been investigated only in cell- 
free systems [36]. 
Here, we have applied the microinjection tech- 
nique [37,38] to investigate the inhibitory effects of 
the tailed 2-5A analog on the replication of 
mengovirus and vesicular stomatitis virus (VSV) in 
HeLa cells. 
2. EXPERIMENTAL 
The oligonucleotide trimer and tetramer 
5 ’ -triphosphate ppp(A2’ p)2A and ppp(A2’ P)~A 
were obtained from PL-Biochemicals. 
The N-substituted morpholine analogs or tailed 
analogs (tetramer 5 ’ -triphosphate and monophos- 
phate) have been described previously 1361. 
2.2. Tailed tetramer core 
The tailed tetramer core was prepared as 
follows: the triethylammonium salt of tailed 
tetramer monophosphate (220 A260 units, 
5.3 pmol), prepared according to Imai et al. [36], 
was digested with bacterial alkaline phosphatases 
(0.5 units) in 500 ~1 of 100 mM Tris-HCl (pH 8.5), 
10 mM MgClz at 37°C for 2.5 h. At the termina- 
tion of the incubation, the reaction mixture was 
heated to 100°C for 5 min and then centrifuged at 
10000 x g. The supernatant was then applied to a 
DEAE-Sephadex A25 column (HCOY form, 1 x 
20 cm) which was subsequently eluted with a linear 
gradient of O-O.15 M triethylammonium bicar- 
bonate (pH 7.6, total volume 500 ml). Appropriate 
fractions were pooled and evaporated to dryness in 
vacua. The residue was taken up in water and the 
resulting solution was evaporated. This process 
was repeated several times to remove all 
triethylammonium bicarbonate. This residue was 
redissolved in dry methanol (200 pi), and the solu- 
tion added dropwise to a stirred solution of NaI in 
acetone (0.1 M, total . volume 2.0 ml). The 
precipitate was isolated by centrifugation, washed 
(3 x) with dry acetone and then dried over PZOS 
for 2 h. The yield of tailed tetramer core was 202 
A260 units (4.9pmo1, 92%). 
327 
Volume 198, number 2 FEBSLETTERS March 1986 
2.3. Viruses and cells 
VSV was grown in human amniotic celfs (UAC) 
and mengovirus was grown in L929 cells, main- 
tained in minimum essential medium (MEM) sup- 
plement~d with 2% fetal calf serum (FCS) and 
stored in aiiquots at - 70°C. Virus titers were 2.5 
x IO* PFU/ml (VSV) and 2.3 x IO’ PFUlml 
(mengo). 
HeLa cells were grown in RPM1 1640 medium 
supplemented with 10% FCS. For the microinjec- 
tion procedure, HeLa cells were cultivated on 
small glass plates (2 mm’) dispersed in 6 cm petri 
dishes in MEM plus 10% FCS. 
For the plaque assay L929 cells were cultured in 
MEM supplemented with 10% FCS and then 
dispensed in aliquots of 1.2 x lo6 cells in the same 
medium into 60 mm diameter Falcon dishes. 
The two cell lines were incubated at 37°C in a 
5% CO2 humidified atmosphere. 
2.4. Cell microinjection 
Mi~roinjection of the compounds into HeLa 
cells was performed according to Graessmann and 
Graessmann 1371, using glass capillaries (tip 
diameter about 0.5-I pm) 131,321. In each experi- 
ment approx. 100-400 cells were microinjected 
with 5 x lo-” ml/cell. Injections were performed 
under a phase contrast microscope 137,381. 
2.5. Infection 
Each glass plate of microinjected cells was 
transferred onto a microwell plate and infected 
with 200~1 of virus dilution, so as to obtain a 
multiplicity of infection (MOI) of 10, just after 
microinje~tion or at the time indicated in the ex- 
periment (in the latter case the cells were main- 
tained in RPM1 with IO% FCS until infection). 
After 1 h incubation at 37”C, the virus was re- 
moved by washing 3 times with the same medium 
and then each well was replenished with 200 ~1 of 
RPM1 + 10% FCS. The cells were enumerated and 
incubation at 37°C continued for another 20 h. At 
this time, the supernatant was collected and stored 
at - 70°C. 
The antiviral activity was determined by a 
monolayer plaque assay: L929 ceil monolayers 
were incubated for 1 h with 200 ~1 of each sample 
diluted lo-105-times. After 1 h adsorption, 5 ml 
melted agar medium (Indubiose IBF I .8%-MEM 2 
x 1: 1 f 2.5 FCS) was added to each 60 mm well. 
The number of pfaques was counted and the titer 
was determined after l-2 days incubation and 
staining with neutral red (0.2% in PBS). 
Tabie I 
Dose-response relationship of the antiviral activity of the 2-5A hexylmorpholine 
triphosphate analog against VSV 
Concentration 
GM) 
Number 
of cells 
PFUlml PFUfcelts % of 
controla 
Expt I 
100 
10 
1 
0= 
160 4 x103 25 I .25 
141 1.2 x l@ 85.X 4.2 
IQ0 8 x IO3 42.1 2.1 
200 4 xl@ 2000 100 
Expt 2 
1 135 2 x102 1.4% 0.13 
0.1 144 8 x 102 5.5 0.5 
0.01 110 3 xio3 27.2 2.5 
Oa 82 9 x10’ 1097.5 100 
a For each experiment he % of control was calculated as a function of the value of 
PFU/cells obtained for VSV-infected HeLa cells which had not been microinjected 
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3. RESULTS AND DISCUSSION 
By using microinjection of 2-5A oligonucleo- 
tides in intact cells, before virus infection, it should 
be possible to assess directly to what extent these 
oligonucleotides are able to suppress virus replica- 
tion. This technique circumvents the problem that 
2-5A molecules by virtue of their 5’-triphosphate 
group cannot penetrate the cells from the outside. 
Furthermore, the microinjection technique permits 
a study of the interplay of degradative enzymes, 
i.e. (2’-5’)-phosphodiesterase, with the in situ an- 
tivifal effects of the 2-5A oligonucleotides. 
The microinjection of 2-5A hexylmorphol~ne 
analogs into HeLa cells before infection with VSV 
or mengovirus at an MO1 of 10 has enabled us to 
compare directly the inhibitory effects of 2-5A 
oligonucleotides on different classes of viruses. At 
the concentration used neither the natural 2-5A 
trimer or tetramer triphosphates nor their 
hexylmorpholine-tailed analogs impaired cell 
viability. Microinjected cells were maintained in 
culture for 3 days without any detectable change in 
their rate of division. In a dose-response xperi- 
ment (table 1) a complete inhibition of VSV 
growth was found when the 2-5A hexylmor- 
pholine analog triphosphate was microinjected at 
10 nM (representing 1 nM inside the cells, con- 
sidering the total volume injected and the average 
CONCENTRATION, ,&I 
When 500pM solutions of the natural 2-5A 
trimer or tetramer triphosphates were microinject- 
ed - representing a concentration of about 50 FM 
inside the cell - (2’-5’)pppA3 and (2’-5’)pppA4 
achieved about 60070 inhibition in the production 
of infectious mengovirus particles. Furthermore, 
microinjection of HeLa cells with a 5OOhM solu- 
tion of the tailed 2-5A tetramer triphosphate 
analog resulted in an almost complete inhibition of 
mengovirus replication (fig. 1). 
Fig. 1. Dose-response relationship of the antiviral The inhibitory effects of natural 2-5A and its 
activity of natural 2-SA and its tailed analog, both tailed analog on mengovirus replication were then 
microinjected immediately before mengovirus infection. directly compared in a dose-response xperiment. 
Concentrations of (2’-5’)ppp& (O---O) and tailed Fig. 1 shows that microinjection of a 100 FM solu- 
(2’-5’)PPPA4 h--. ) are indicated on the abscissa. tion of tetramer 2-5A triphosphate gave an inhibi- 
volume of the cell). This is at least 20-fold lower 
than the concentration of natural 2-5A in IFN- 
treated EMC virus-infected L cells [6]. These 
results confirm previous observations that VSV 
growth is sensitive to inhibition by natural 2-5A 
[39,40] and 2’-0-phosphoglyceryl derivatives of 
2-5A [41], although the 2-5A system does not ap- 
pear to be activated in intact cells [42,43]. 
The present data confirm the ability of 2-5A to 
block VSV replication, when the oligonucleotide is 
present at the beginning of the infection [40]. 
Upon microinjection of natural 2-SA complete in- 
hibition of VSV growth was achieved at 
100 nM-1 PM 2-5A inside the cell (not shown) 
[39,41]. The work presented here shows that in in- 
tact cells the tailed analogs are at least 100-fold 
more active than natural 2-5A. Moreover, the ac- 
tivity of the 2-5A hexylmorpholine analog 
towards VSV is at least IOOO-fold higher than that 
obtained with the phosphoglyceryl derivatives of 
2-5A 1411, although the two analogs have com- 
parable activity and stability in an in vitro assay 
[36,41]. 
Since 2-5A has not been detected in IFN-treated 
VSV-infected cells [42,43], it was of interest to in- 
vestigate the antiviral activity of 2-5A (or its 
analogs) towards other types of viruses, known to 
activate the 2-5A pathway in the presence of IFN 
in intact cells [6,19]. Thus, we tested 2-5A and its 
hexylmorpholine analog on mengovirus, a picor- 
navirus, belonging to the same group as the exten- 
sively studied EMC virus. Paradoxically, microin- 
jection of natural 2-5A and even its hexylmor- 
pholine analog proved poorly active in inhibiting 
mengovirus growth. 
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TabIe 2 
Antiviral activity against VSV and mengovirus of the 2-5A hexylmorpholine core and monophosphate 
analogs 
Concentration 
OtM) 
Number 
of cells 
PFUlml PFU/ceIls @IO of 
control” 
Expt 3: Mengovirus 
Core 
Monophosphate 
500 
500 
500 
oa 
Expt 4: VSV 
Core 100 
10 
1 
0” 
60 2.5 x IO4 416.6 8.8 
52 5 x104 961.5 20.4 
239 6.9 x 10’ 288.7 6.1 
180 8.5 x 10’ 4122 100 
124 1 x104 80.6 520 
15s 2 x104 129 832.3 
112 4 x lo3 35.7 230.4 
129 2 x103 15.5 100 
a For each experiment he 070 of control was calculated as a function of the value of PFU/cells obtained 
for virus-infected HeLa cells which had not been microinjected 
tion of only 20% and no inhibition was found at 
10 ,uM. For the tailed analog, maximum inhibition 
of virus rephcation was achieved at 30~M (3 FM 
intracellular) and above; 50% inhibition was ob- 
tained upon microinjection of a 15 PM solution 
(about 1.5 ,uM intraceilular). Since maximal inhibi- 
tion of mengovirus replication by tailed 2-5A was 
achieved only at a rather high concentration 
(30 FM intracellularly) (fig.l), i.e. at least 150-fold 
higher than that of natural 2-SA in IFN-treated 
EMC virus-infected L cells [6], we conclude that 
mengovirus was relatively refractory to 2-5A and 
its analogs. This high resistance of mengovirus to 
the antiviral effect of 2-5A is in keeping with 
previous observations showing the lack of 2-5A- 
dependent RNase activation by 2-5A in cell-free 
extracts obtained from EMU-infected cells [44,45]. 
The present results suggest hat this situation may 
also occur in intact ceils. However, other 
hypotheses could be considered to explain the 
lower sensitivity of mengovirus to the antiviral ef- 
fect of 2-SA, such as a more difficult diffusion or 
access of the oligonu~ieotides to the viral replica- 
tion site in mengovirus-infected cells [46,47]. 
Part of the improvement of antiviral activity 
towards mengovirus observed here with microin- 
jetted hexylmorpholine analog could be due to 
catabolic products liberated by the intracellular 
processing of the tailed analog. This is confirmed 
by the microinjection of the core and the 
monophosphate hexylmorpholine analogs, which 
gave maximal inhibition of mengovirus growth at 
500,uM (table 2). In contrast, VSV (shown in our 
experimental system to be an indicator of the 
2-SA-dependent RNase activation) was complete- 
ly resistant to different concentrations of the 
tailed-core analog (table 2). Since it is known that 
core 2-5A neither binds 1191 nor activates [29] the 
2-SA-dependent RNase, this also indicates that 
the inhibition of mengovirus replication by the lat- 
ter analogs might be unrelated to the activation of 
the 2-SA-dependent endonuclease. 
The microinjection technique represents a 
powerful tool to monitor in situ the antiviral ef- 
fects of 225A analogs as well as their interplay 
with different enzymes, be it anabolic or catabolic. 
By this technique any new 2%SA analog [48,49] can 
be monitored for its fate within the ceil. The 
microinjection technique may thus have an impor- 
tant predictive advantage in terms of quantitative 
biological activity of various 2-5A analogs in in- 
tact cells. 
Finally, the microinjection technique offers the 
possibility of investigating the effects of 2-SA 
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derivatives on different classes of viruses in- 
dependently of the physiological role they could 
play in the ‘natural’ response to interferon. 
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